InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

Current share price for NTI : $0.016 0.001 (5.88%)+

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Change of Director's Interest Notice 6 Dec 2024 2:27PM $0.056 $0.016 fallen by 71.43%
$26 Resignation of Joint Company Secretary 2 Dec 2024 8:25PM $0.065 $0.016 fallen by 75.38%
$26 Secondary Trading Notice 2 Dec 2024 5:29PM $0.065 $0.016 fallen by 75.38%
$26 Application for quotation of securities - NTI 2 Dec 2024 5:21PM $0.065 $0.016 fallen by 75.38%
$26 Neurotech Receives US ODD in Rett Syndrome 26 Nov 2024 9:45AM $0.066 $0.016 fallen by 75.76%
$26 NTI Receives Ethics Approval to Commence Human PK Study 25 Nov 2024 8:11AM $0.069 $0.016 fallen by 76.81%
$26 Notification of cessation of securities - NTI 20 Nov 2024 6:06PM $0.066 $0.016 fallen by 75.76%
$26 Results of Annual General Meeting 20 Nov 2024 12:43PM $0.064 $0.016 fallen by 75%
$26 2024 AGM Chairman Address and Investor Presentation 20 Nov 2024 8:15AM $0.061 $0.016 fallen by 73.77%
$26 Positive Genomic Effects of NTI164 in PANDAS/PANS Patients 15 Nov 2024 8:20AM $0.057 $0.016 fallen by 71.93%
$26 New Scientific Publication Highlights Benefits of NTI164 12 Nov 2024 12:19PM $0.055 $0.016 fallen by 70.91%
$26 Proposed issue of securities - NTI 11 Nov 2024 8:53AM $0.053 $0.016 fallen by 69.81%
$26 Neurotech Appoints Dr Anthony Filippis as MD/CEO 11 Nov 2024 8:27AM $0.053 $0.016 fallen by 69.81%
$26 Quarterly Activities/Appendix 4C Cash Flow Report 23 Oct 2024 9:28AM $0.050 $0.016 fallen by 68%
$26 Notice of Annual General Meeting/Proxy Form 16 Oct 2024 5:44PM $0.048 $0.016 fallen by 66.67%
$26 Becoming a substantial holder 8 Oct 2024 8:18PM $0.050 $0.016 fallen by 68%
$26 US FDA Response to Orphan Drug Request in PANDAS/PANS 4 Oct 2024 8:52AM $0.058 $0.016 fallen by 72.41%
$26 Upcoming Presentation of Rett Syndrome Clinical Data 24 Sep 2024 9:12AM $0.060 $0.016 fallen by 73.33%
$26 Change of Director's Interest Notice 20 Sep 2024 6:25PM $0.060 $0.016 fallen by 73.33%
$26 Notification regarding unquoted securities - NTI 20 Sep 2024 6:22PM $0.060 $0.016 fallen by 73.33%
$26 Notification of cessation of securities - NTI 18 Sep 2024 4:53PM $0.068 $0.016 fallen by 76.47%
$26 Secondary Trading Notice 18 Sep 2024 4:35PM $0.068 $0.016 fallen by 76.47%
$26 Notification regarding unquoted securities - NTI 18 Sep 2024 4:10PM $0.068 $0.016 fallen by 76.47%
$26 Application for quotation of securities - NTI 18 Sep 2024 4:08PM $0.068 $0.016 fallen by 76.47%
$26 Becoming a substantial holder 17 Sep 2024 7:22PM $0.069 $0.016 fallen by 76.81%

101 - 125 of 702 results

Page 5 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.